<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563989</url>
  </required_header>
  <id_info>
    <org_study_id>K171009J</org_study_id>
    <nct_id>NCT03563989</nct_id>
  </id_info>
  <brief_title>STENTYS Xposition S in the Treatment of Chronic Total Artery Occlusion</brief_title>
  <acronym>SXS-CTO</acronym>
  <official_title>STENTYS Xposition S in the Treatment of Chronic Total Artery Occlusion (SXS-CTO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intro: Chronic total occlusions (CTO) are the most severe coronary lesions. Negative distal&#xD;
      vessel remodeling occurs in these lesions, leading to reduction of artery diameter. Treatment&#xD;
      of CTO with percutaneous coronary intervention (PCI) is associated with good clinical&#xD;
      outcomes. However, QCA and IVUS studies showed a notable lumen and vessel enlargement distal&#xD;
      to recanalized CTO. In addition, optical tomography (OCT) studies showed high rates of stent&#xD;
      strut malapposition and incomplete stent strut coverage after CTO PCI. The Stentys Xposition&#xD;
      S is a self-apposing stent device which lowers stent strut malapposition rates. Its safety&#xD;
      and effectiveness has been demonstrated in STEMI and stable coronary patients but never&#xD;
      investigated in CTO lesions.&#xD;
&#xD;
      Hypothesis/Objective To investigate whether self-expanding stents are more effective than&#xD;
      balloon-expandable stents for reducing stent malapposition at 6 months after implantation in&#xD;
      patients with CTO undergoing percutaneous coronary intervention.&#xD;
&#xD;
      Method Pilot randomized study. Patients are randomized to receive either self-expandable&#xD;
      stent or balloon expandable stent to perform CTO-PCI. Follow-up coronary angiography is&#xD;
      performed at 6 months post-PCI. Stent malapposition is evaluated by OCT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 26, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>strut malapposition at six months measured by OCT</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of uncovered struts</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lumen diameter (mm)</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restenosis</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina pectoris</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Total Occlusion</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Stentys Xposition S Self-Apposing stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STENTYS Xposition S Sirolimus Eluting Self-Apposing Coronary Stent System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Balloon-expandable stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional Balloon-expandable drug eluting stents in effect at the time of the study, in compliance with applicable contracts made between Hospital and suppliers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of Stent (PCI)</intervention_name>
    <description>Treatment of CTO with Percutaneous Coronary Intervention (PCI) Patients are randomized to receive either self-expandable stent or balloon expandable stent</description>
    <arm_group_label>Conventional Balloon-expandable stent</arm_group_label>
    <arm_group_label>Stentys Xposition S Self-Apposing stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥ 18 years;&#xD;
&#xD;
          -  CTO referred for PCI&#xD;
&#xD;
          -  Diameter of the Target vessel for PCI between 2.5 and 4.5mm&#xD;
&#xD;
          -  Agreement to participate and signed informed consent after information&#xD;
&#xD;
          -  Affiliation to Social Security System&#xD;
&#xD;
          -  French comprehension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women, breast-feeding,&#xD;
&#xD;
          -  History of an allergic reaction or significant sensitivity to any stent component or&#xD;
             to contrast dye&#xD;
&#xD;
          -  Intrastent CTO&#xD;
&#xD;
          -  Major calcifications in the CTO&#xD;
&#xD;
          -  Inclusion in another interventional study&#xD;
&#xD;
          -  Person under guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Paris - CHU HENRI MONDOR</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MADJID BOUKANTAR, MD</last_name>
      <phone>+33149812111</phone>
      <email>madjid.boukantar@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 28, 2018</study_first_submitted>
  <study_first_submitted_qc>June 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>August 10, 2018</last_update_submitted>
  <last_update_submitted_qc>August 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic total occlusion</keyword>
  <keyword>Self-expandable stent</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

